Gadopiclenol
Elucirem (gadopiclenol) is a small molecule pharmaceutical. Gadopiclenol was first approved as Elucirem on 2022-09-21.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Elucirem
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gadopiclenol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ELUCIREM | Guerbet | N-216986 RX | 2022-09-21 | 7 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| elucirem | New Drug Application | 2022-10-12 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
GADOPICLENOL, ELUCIREM, GUERBET | |||
| 2027-09-21 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | 1 | — | — | — | 3 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Central nervous system diseases | D002493 | HP_0002011 | G96.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
| Pharmacokinetics | D010599 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GADOPICLENOL |
| INN | gadopiclenol |
| Description | Gadopiclenol, sold under the brand name VUEWAY among others, is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. Gadopiclenol is a paramagnetic macrocyclic non-ionic complex of gadolinium.
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 933983-75-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297634 |
| ChEBI ID | — |
| PubChem CID | 16223405 |
| DrugBank | — |
| UNII ID | S276568KOY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elucirem
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more